One example is the glucagon-like peptide-1 (GLP-1) pathway, wherein synthetic peptide agonists of the GLP-1 receptor drive weight loss and are currently approved for the treatment of diabetes and obesity [26]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.